Cite
HARVARD Citation
Waterhouse, D. et al. (n.d.). 60MO Real-world overall and progression-free survival for first-line immunotherapy-based regimens in advanced non-small cell lung cancer. Immuno-oncology technology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Waterhouse, D. et al. (n.d.). 60MO Real-world overall and progression-free survival for first-line immunotherapy-based regimens in advanced non-small cell lung cancer. Immuno-oncology technology. p. . [Online].